Source comparison
Tesamorelin Side Effects: Clinical Comparison
Understanding how tesamorelin side effects compare to other growth hormone secretagogues and direct GH administration helps contextualize the risk-benefit profile for specific research applications. Tesamorelin 2mg daily GHRH analog. Stimulates pulsatile GH re
This comparison does not assign a generated winner or score.
- Understanding how tesamorelin side effects compare to other growth hormone secretagogues and direct GH administration helps contextualize the risk-benefit profile for specific research applications.
- Tesamorelin 2mg daily
- GHRH analog. Stimulates pulsatile GH release
- 35–45% incidence, mild to moderate, resolves by week 8
- 12–18% arthralgia, onset weeks 4–8, typically mild
- 10–15% peripheral edema, dose-dependent
- HbA1c +0.2–0.4% in 8–12%, reversible
- Lowest systemic side effect burden among GH secretagogues; localized reactions dominate
- Ipamorelin 200–300mcg daily
- Ghrelin mimetic. Selective GH release
- 15–25% incidence, less frequent than GHRH analogs
- 8–12% arthralgia, generally milder than tesamorelin
- 5–10% edema, lower than GHRH analogs
- Minimal glucose impact, <5% HbA1c elevation
- Better tolerability for musculoskeletal and metabolic effects, but lower peak GH amplitude
- CJC-1295 (with DAC) 2mg weekly
- Long-acting GHRH analog
- 20–30% incidence, persistent nodules reported
- 20–30% arthralgia due to sustained GH elevation
- 15–25% edema, higher than pulsatile protocols
- HbA1c +0.3–0.6%, higher risk in sustained-release formulations
- Sustained GH elevation increases systemic side effects; less physiological than pulsatile release
- Recombinant GH 2–4 IU daily
- Direct GH replacement
- <5% (not subcutaneous inflammatory response)
- 30–50% arthralgia, dose-dependent and common
- 25–40% edema, most frequent side effect
- HbA1c +0.4–0.8%, significant insulin resistance risk
- Highest side effect burden; bypasses endogenous regulation entirely
- The comparison reveals a clear pattern: agents that preserve pulsatile GH secretion (tesamorelin, ipamorelin) produce fewer systemic side effects than those that create sustained supraphysiological GH levels (CJC-1295 with DAC, recombinant GH). Tesamorelin's primary tolerability challenge is localized injection site reactions. A manageable issue with proper rotation technique. While systemic effects like arthralgia and glucose impact remain lower than direct GH administration.